Highly sensitive patient-specific real-time PCR SNP assay for chimerism monitoring after allogeneic stem cell transplantation

Laboratory Hematology

Volumn 12, Issue 1, 2006, Pages 39-46

  Eshel, Rinat ^a   Vainas, Oded ^a   Shpringer, Meirav ^a   Naparstek, Elizabeth ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chimerism; SNP; Stem cell transplantation

Indexed keywords

DNA;

ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHIMERA; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DNA DETERMINATION; ECONOMIC ASPECT; HUMAN; MEDICAL TECHNOLOGY; MINIMAL RESIDUAL DISEASE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

FEMALE; GRAFT REJECTION; HUMANS; MALE; MONITORING, PHYSIOLOGIC; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; STEM CELL TRANSPLANTATION; TANDEM REPEAT SEQUENCES; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 33645372559     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: 10.1532/LH96.05034     Document Type: Article

References (40)

1. Horowitz MM, Gale RP, Sondel PM, et al. Graft versus leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-556.
2. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767-776.
3. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23:1553-1562.
4. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
5. Peggs KS, Mackinnon S. Cellular therapy: donor lymphocyte infusion. Curr Opin Hematol. 200;8:349-354.
6. Slavin S, Morecki S, Weiss L, Or R. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res. 2002;11:265-276.
7. Gilleece MH, Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphom. 2003;44:23-28.
8. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
9. Haddad N, Rowe JM. Current indications for reduced-intensity allogeneic stem cell transplantation. Best Pract Res Clin Haematol. 2004;17:377-386.
10. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogencic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant. 2004;33:691-696.
11. Baron F, Beguin Y. Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:351-359.
12. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
13. Dey BR, McAfee S, Colby C, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2003;9:320-329.
14. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100:3108-3114.
15. Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoictic cell transplantation following nonmyeloablative conditioning. Blood. 2004;103:790-795.
16. Kolb HJ, Simoes B, Schmid C. Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. Curr Opin Oncol. 2004; 16:167-173.
17. Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations for a workshop at the 2001 tandem meetings. Biol Blood Marrow Transplant. 2001;7:473-485.
18. Ginsburg D, Antin JH, Smith BR, et al. Analysis using DNA sequence polymorphism. J Clin Invest. 1985;75:590-603.
19. Screenan JJ, Pettay JD, Tbakhi A, et al. The use of amplified variable number of tandem repeats (VNTR) in the detection of chimerism following bone marrow transplantation: a comparison with restriction fragment length polymorphism (RFLP) by Southern blotting. Am J Clin Pathol. 1997;107:292-298.
20. Frankel W, Chan A, Corringham RE, et al. Detection of chimerism and early engraftment after allogeneic peripheral blood stem cell or bone marrow transplantation by short tandem repeats. Am J Hematol. 1996;52:281-287.
21. Thiede C, Florek M, Bornhauser M, et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeats markers and fluorescence detection. Bone Marrow Transplant. 1999;23:1055-1060.
22. Thiede C, Bornhauser M, Oelschlagel U, et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia. 2001;15:293-302.
23. Schichman SA, Suess P, Vertino AM, Gray PS. Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment. Bone Marrow Transplant. 2002;29:243-248.
24. Schraml E, Lion T. Interference of dye-associated fluorescence signals with quantitative analysis of chimerism by capillary electrophoresis. Leukemia. 2003;17:221-223.
25. Perez-Simon JA, Caballero D, Diez-Campelo M, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia. 2002;16:1423-1431.
26. Valcarcel D, Martino R, Caballero D, et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2003;31:387-392.
27. Uzunel M, Mattsson J, Brune M, et al. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood. 2003;101:469-472.
28. Taillon-Miller P, Piernot EE, Kwok PY. Efficient approach to unique single-nucleotid polymorphism discovery. Genome Research. 1999;9:499-505.
29. Salisbury BA, Pungliya M, Choi JY, et al. SNP and haplotype variation in the human genome. Mutat Res. 2003;526:53-61.
30. Oliver DH, Thompson RE, Griffin CA, Eshleman JR. Use of Single Nucleotide Polymorphisms (SNP) and real-time polymerase chain reaction for bone marrow engraftment analysis. J Mol Diag. 2000;12:202-207.
31. Hochberg EP, Miklos DB, Neuberg D, et al. A novel rapid single nucleotid polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood. 2003;101:363-369.
32. Maas F, Schaap N, Kolen S, et al. Quantification of donor and recipient hematopoietic cells by real-time PCR of single nucleotide polymorphism. Leukemia. 2003;17:621-629.
33. Fredriksson M, Barbany G, Liljedahl U, et al. Assessing hematopoietic chimerism after allogeneic stem cell transplantation by multiplex SNP genptyping using microarrays and quantitative analysis of SNP alleles. Leukemia. 2004;18:255-266.
34. Thiede C, Bornhauser M, Ehninger G. Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2004;112:16-23.
35. Shimoni A, Nagler A. Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations. Leukemia. 2001;15:1967-1975.
36. Elmaagacli AH. Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation. Int J Hematol. 2002;76 (Suppl) 2:204-205.
37. Shastry BS. SNP alieles in human disease and evolution. J Hum Genet. 2002;47:561-566.
38. den Haan JM, Meadows LM, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998;279:1054-1057.
39. Cavet J, Dickinson AM, Norden J, et al. Interferon-gamma and interleukin-6 gene polymorphism associate with graft-versus-host disease in HLA-mathced sibling bone marrow transplantation. Blood. 2001;98:1594-1600.
40. Wu CJ, Hochberg EP, Rogers SA, et al. Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol. 2003;31:924-933.